Morgan Stanley lowered the firm’s price target on Zimmer Biomet (ZBH) to $95 from $115 and keeps an Equal Weight rating on the shares. Q1 was “optically ok,” but a tough U.S. knee number and second half ramp implied in the guidance is “tough to underscore,” the analyst tells investors. Street numbers are likely coming down about 7%-8% in 2026 on tariffs, the analyst estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet price target lowered to $112 from $125 at RBC Capital
- Zimmer Biomet price target lowered to $104 from $119 at Raymond James
- Zimmer Biomet price target lowered to $115 from $130 at Baird
- Cautious Hold on Zimmer Biomet Amid Mixed Performance and Strategic Adjustments
- Zimmer Biomet price target lowered to $110 from $135 at BofA